ArticleHealthcare (Basel, Switzerland)2025
Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study.
Article in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundMany biological drugs have a rival version produced from different cell lines by other manufacturers; these drugs are referred to as biosimilars. By providing accurate information, encouraging patient and medical community acceptance, and advocating for their appropriate usage, pharmacists can play a crucial role in supporting the uptake of biosimilar medicines.
aimThis study aimed to assess pharmacists' knowledge and attitudes toward biosimilar medicines in the Aseer region in Saudi Arabia.
methodsThe study employed a descriptive, cross-sectional design using an anonymous online self-administered questionnaire. The questionnaire was developed by adapting a previously validated instrument and consisted of three sections: demographic data, knowledge about biosimilars, and attitudes toward biosimilars. Two non-probability sampling approaches, i.e., convenience and snowball sampling, were using for data collection.
resultsA total of 298 pharmacists participated in the current study. Overall, a total of 135 (45.3%) demonstrated good knowledge of biosimilar medicines, while 163 (54.7%) exhibited poor knowledge. The median knowledge score among the study participants was 5 (5-6). Only 26.2% of pharmacists in the current study correctly identified that biosimilars were not generics and not interchangeable with reference biologics. More experienced pharmacists and those working in industry-related sectors demonstrated greater knowledge of biosimilars (
conclusionsThe current study revealed knowledge gaps regarding biosimilar medicines among pharmacists. Targeted educational initiatives, continuing professional development opportunities, and enhanced curricular content could be implemented to address these gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.